Cryptococcus neoformans gene expression during murine macrophage infection

Weihua Fan1, Peter R Kraus, Marie-Josee Boily

  • 1Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA.

Eukaryotic Cell
|August 10, 2005
PubMed

Insights

Cryptococcus neoformans adapts to macrophage environments by altering gene expression, up-regulating nutrient transporters and stress responses. This study reveals key pathways, like the Gpa1-cyclic AMP-protein kinase A pathway, crucial for fungal virulence.

Area of Science:

  • Mycology
  • Pathogenesis
  • Molecular Biology

Background:

  • Cryptococcus neoformans is a fungal pathogen that survives within macrophages, establishing latent infections.
  • Understanding how C. neoformans adapts to the intracellular macrophage environment is crucial for explaining its pathogenesis.

Purpose of the Study:

  • To investigate the transcriptional response of C. neoformans to phagocytosis by murine macrophages.
  • To identify genes and pathways involved in fungal adaptation and virulence within macrophages.

Main Methods:

  • DNA microarray technology to analyze gene expression profiles.
  • Quantitative reverse transcription-PCR and a green fluorescent protein reporter strain for verification.
  • Analysis of gpa1 and pka1 mutants in macrophage infection models.

Main Results:

  • Upregulation of membrane transporters (hexoses, amino acids, iron), oxidative stress response genes, autophagy, peroxisome, and lipid metabolism genes.
  • Increased expression of the mating type locus (MAT) and the Gpa1-cyclic AMP-protein kinase A pathway.
  • Downregulation of ribosome-related functions, indicating reduced translation as a key response.

Conclusions:

  • The study provides a comprehensive gene expression profile of C. neoformans adapting to intracellular macrophage infection.
  • The Gpa1-cyclic AMP-protein kinase A pathway is confirmed as a critical virulence factor.
  • This research identifies potential novel virulence attributes for therapeutic targeting.